...
首页> 外文期刊>Urologia internationalis >Outcomes for Patients after Resection of Pulmonary Metastases from Clear Cell Renal Cell Carcinoma: 18 Years of Experience
【24h】

Outcomes for Patients after Resection of Pulmonary Metastases from Clear Cell Renal Cell Carcinoma: 18 Years of Experience

机译:从透明细胞肾细胞癌切除肺转移后患者的结果:18年的经验

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Clear cell renal cell carcinoma (ccRCC) is the most common kidney tumor. If feasible, metastasectomy is preferably indicated in metastatic disease. Objective: The aim of this study was to determine the outcome of patients after pulmonary metastasectomy (PM). Methods: PM for ccRCC was performed in 35 patients in the period of January 2001-2019. Clinical characteristics, type of surgery, histopathology results, and follow-up data were recorded. Progression-free survival (PFS) after PM and overall survival (OS) were defined as outcome endpoints. Results: A total of 77 PMs were performed in 35 patients after nephrectomy for ccRCC. The mean size of pulmonary metastasis was 19.0 mm (4-90). With a median follow-up after PM of 79.2 months, the 3- and 5-year OS rates were 63.5 and 44.9%, respectively. The only statistically significant prognostic factor affecting both PFS (p = 0.019) and OS (p = 0.015) was the dimension of pulmonary metastases. Conclusions: The prognosis of metastatic ccRCC is generally poor, particularly in cases of larger size of metastasis. PM might improve the individual prognosis of patients with lung metastasis even in cases with higher number of metastases, bilaterality, synchronous metastasis, or a short progression-free interval after nephrectomy.
机译:简介:透明细胞肾细胞癌(CCRCC)是最常见的肾肿瘤。如果可行,则优选在转移性疾病中表明转移术。目的:本研究的目的是确定肺部转移切除术后患者的结果(PM)。方法:PM为CCRCC,在2001 - 2019年1月的35名患者中进行。记录了临床特征,手术类型,组织病理学结果和随访数据。 PM和总存活后的无进展生存期(PFS)定义为结果终点。结果:CCRCC肾切除术后35名患者中共进行了77分。肺转移的平均尺寸为19.0 mm(4-90)。下午79.2个月后的中位随访,3岁和5年的OS率分别为63.5和44.9%。影响PFS(P = 0.019)和OS(P = 0.015)的唯一统计学上显着的预后因素是肺转移的尺寸。结论:转移性CCRCC的预后通常差,特别是在大小的转移的情况下。下午可能改善肺转移患者的个体预后,即使在肾切除术后的较高的转移,双侧,同步转移或短期进展间隔的情况下,也可以改善肺转移患者的个体预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号